Continued evidence for safety of endoscopic retrograde cholangiopancreatography during pregnancy

Table 2 Endoscopic retrograde cholangiopancreatography indications, outcomes, and complications

	All patients (n = 20)	Age 18-21 (n = 7)	Age 22-29 (n = 8)	Age≥30 (n = 5)
Trimester	2 (0.77)	2.14 (0.89)	2 (0.92)	1.8 (0.44)
Indication for ERCP
Common bile duct stone	17	5	8	4
Gallstone pancreatitis	2	2	0	0
Cholangitis	1	0	0	1
Protective shielding stated in note	8	3	1	4
Anesthesia
Midazolam	17	6	7	4
Fentanyl	5	2	3	0
Propofol	3	1	1	1
Meperidine	13	4	5	4
Fluoroscopy dose/min	3.8 (5.5)	6.5 (8.5)	2.2 (2.8)	2.7 (3.0)
Spot radiographs	6	2	3	1
Sphincterotomy	18	5	8	5
Stenting	4	2	1	1
2 ≥ stones removed	5	1	1	3
Post ERCP antibiotic
Piperacillin/tazobactam	2	0	1	1
Post-ERCP complications
Pancreatitis	2	1	1	0
Oversedation	0	0	0	0
Perforation	0	0	0	0
Cholangitis	0	0	0	0
Contrast dye reaction	0	0	0	0
Bleeding	2	1	1	0
Cholecystectomy
Prior history of receiving	3	0	1	2
Post ERCP	11	5	5	1

ERCP: Endoscopic retrograde cholangiopancreatography.